An Open Label, Randomised, Six-way Crossover, Single Dose Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
Price : $35 *
At a glance
- Drugs Batefenterol (Primary) ; Batefenterol/fluticasone furoate (Primary) ; Fluticasone furoate
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 30 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 03 Mar 2014 New trial record